Artificial Intelligence (AI) in Epidemiology Market Size, Share, and Trends 2024 to 2034

The global artificial intelligence (AI) in epidemiology market size is calculated at USD 894.53 million in 2025 and is forecasted to reach around USD 7,853.29 million by 2034, accelerating at a CAGR of 27.30% from 2025 to 2034. The North America artificial intelligence (AI) in epidemiology market size surpassed USD 295.13 million in 2024 and is expanding at a CAGR of 27.45% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.

  • Last Updated : February 2025
  • Report Code : 4458
  • Category : ICT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology (Premium Insights)

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Artificial Intelligence (AI) in Epidemiology Market 

5.1. COVID-19 Landscape: Artificial Intelligence (AI) in Epidemiology Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Artificial Intelligence (AI) in Epidemiology Market, By Deployment

8.1. Artificial Intelligence (AI) in Epidemiology Market, by Deployment

8.1.1 Web-based

8.1.1.1. Market Revenue and Forecast

8.1.2. Cloud-based

8.1.2.1. Market Revenue and Forecast

Chapter 9. Global Artificial Intelligence (AI) in Epidemiology Market, By Application Infection

9.1. Artificial Intelligence (AI) in Epidemiology Market, by Application Infection

9.1.1. Prediction and Forecasting

9.1.1.1. Market Revenue and Forecast

9.1.2. Disease and Syndromic Surveillance

9.1.2.1. Market Revenue and Forecast

Chapter 10. Global Artificial Intelligence (AI) in Epidemiology Market, By End-use 

10.1. Artificial Intelligence (AI) in Epidemiology Market, by End-use

10.1.1. Government and State Agencies

10.1.1.1. Market Revenue and Forecast

10.1.2. Research labs

10.1.2.1. Market Revenue and Forecast

10.1.3. Pharmaceutical and Biotechnology Companies

10.1.3.1. Market Revenue and Forecast

10.1.4. Healthcare Providers

10.1.4.1. Market Revenue and Forecast

Chapter 11. Global Artificial Intelligence (AI) in Epidemiology Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Deployment

11.1.2. Market Revenue and Forecast, by Application Infection

11.1.3. Market Revenue and Forecast, by End-use

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Deployment

11.1.4.2. Market Revenue and Forecast, by Application Infection

11.1.4.3. Market Revenue and Forecast, by End-use

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Deployment

11.1.5.2. Market Revenue and Forecast, by Application Infection

11.1.5.3. Market Revenue and Forecast, by End-use

11.2. Europe

11.2.1. Market Revenue and Forecast, by Deployment

11.2.2. Market Revenue and Forecast, by Application Infection

11.2.3. Market Revenue and Forecast, by End-use

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Deployment

11.2.4.2. Market Revenue and Forecast, by Application Infection

11.2.4.3. Market Revenue and Forecast, by End-use

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Deployment

11.2.5.2. Market Revenue and Forecast, by Application Infection

11.2.5.3. Market Revenue and Forecast, by End-use

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Deployment

11.2.6.2. Market Revenue and Forecast, by Application Infection

11.2.6.3. Market Revenue and Forecast, by End-use

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Deployment

11.2.7.2. Market Revenue and Forecast, by Application Infection

11.2.7.3. Market Revenue and Forecast, by End-use

11.3. APAC

11.3.1. Market Revenue and Forecast, by Deployment

11.3.2. Market Revenue and Forecast, by Application Infection

11.3.3. Market Revenue and Forecast, by End-use

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Deployment

11.3.4.2. Market Revenue and Forecast, by Application Infection

11.3.4.3. Market Revenue and Forecast, by End-use

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Deployment

11.3.5.2. Market Revenue and Forecast, by Application Infection

11.3.5.3. Market Revenue and Forecast, by End-use

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Deployment

11.3.6.2. Market Revenue and Forecast, by Application Infection

11.3.6.3. Market Revenue and Forecast, by End-use

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Deployment

11.3.7.2. Market Revenue and Forecast, by Application Infection

11.3.7.3. Market Revenue and Forecast, by End-use

11.4. MEA

11.4.1. Market Revenue and Forecast, by Deployment

11.4.2. Market Revenue and Forecast, by Application Infection

11.4.3. Market Revenue and Forecast, by End-use

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Deployment

11.4.4.2. Market Revenue and Forecast, by Application Infection

11.4.4.3. Market Revenue and Forecast, by End-use

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Deployment

11.4.5.2. Market Revenue and Forecast, by Application Infection

11.4.5.3. Market Revenue and Forecast, by End-use

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Deployment

11.4.6.2. Market Revenue and Forecast, by Application Infection

11.4.6.3. Market Revenue and Forecast, by End-use

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Deployment

11.4.7.2. Market Revenue and Forecast, by Application Infection

11.4.7.3. Market Revenue and Forecast, by End-use

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Deployment

11.5.2. Market Revenue and Forecast, by Application Infection

11.5.3. Market Revenue and Forecast, by End-use

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Deployment

11.5.4.2. Market Revenue and Forecast, by Application Infection

11.5.4.3. Market Revenue and Forecast, by End-use

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Deployment

11.5.5.2. Market Revenue and Forecast, by Application Infection

11.5.5.3. Market Revenue and Forecast, by End-use

Chapter 12. Company Profiles

12.1. Cerner Corporation

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Cognizant

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. eClinical Works Inc

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Alphabet Inc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Intel Corporation

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Epic Systems Corporation

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Microsoft Corporation

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Meditech

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Komodo Health

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Siemens Healthineers

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global artificial intelligence (AI) in epidemiology market size is expected to increase USD 7,853.29 million by 2034 from USD 702.70 million in 2024.

The global artificial intelligence (AI) in epidemiology market will register a growth rate of 27.30% between 2025 and 2034.

The major players operating in the artificial intelligence (AI) in epidemiology market are Cerner Corporation, Cognizant, eClinical Works Inc, Alphabet Inc, Intel Corporation, Epic Systems Corporation, Microsoft Corporation, Meditech, Komodo Health, Siemens Healthineers, Bayer Healthcare, SAS Institute, Cardiolyse, Predixion Healthcare (Jvion LLC) Others.

The driving factor of the artificial intelligence (AI) in epidemiology market are the rising importance of artificial intelligence in public health.

North America region will lead the global artificial intelligence (AI) in epidemiology market during the forecast period 2025 to 2034.

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client